Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab and ASCT in Relapsed Multiple Myeloma
NCT04965155Phase 2Active, not recruiting
- Sponsor
- EMN Trial Office
- Start
- Mar 2021
- Primary completion
- Nov 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in multiple myeloma (MM), sponsored by EMN Trial Office. Started Mar 2021; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04965155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965155.